Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Looking to defend its giant cardiometabolic health franchise, Eli ... allows Lilly to apply the long-acting technology to as many as four of its drug compounds. That may help the company stave ...

Please send tips or suggestions to [email protected]) May 27, 2025 Eli ... company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly ...

Among these gamechangers undoubtedly lies the introduction of fluoxetine (Prozac) by Eli Lilly and Company in 1987. The search for a drug specifically targeting depression began with the work of ...

The ACS Women Chemists Committee (WCC) and Eli Lilly and Company sponsor a program to provide funding for undergraduate, graduate, and postdoctoral female chemists to travel to meetings to present the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

In family business, focusing on the current leader is hazardous. Here are common issues with focusing on the current family enterprise leader.

The EMA's human medicines committee has said it does not recommend approval of Eli Lilly's anti-amyloid Alzheimer's disease treatment Kisunla, saying its modest benefits don't outweigh its risks.

New Yorkers will line the streets on Sunday to applaud and encourage more than 50,000 runners. PRWeek checks in with participants and asks about parallels between training and the PR profession.